#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Encephalopathy neonatal Hodgkin's disease recurrent Acquired C1 inhibitor deficiency Rheumatoid arthritis MELAS syndrome Arterial disorder Mucopolysaccharidosis III Fibrodysplasia ossificans progressiva Non-Hodgkin's lymphoma Retinopathy of prematurity Haematological malignancy Short-bowel syndrome Fallopian tube cancer Neurofibroma Glycogen storage disease type V More trials…

    Learn about Rare Diseases

    Testicular leiomyosarcoma Familial haemophagocytic lymphohistiocytosis Hereditary hypophosphataemic rickets – Trials in Disease Pulmonary sarcoidosis Angiosarcoma metastatic – Life with Disease Alternating hemiplegia of childhood – Trials in Disease Medulloblastoma recurrent – Diagnostics Langerhans’ cell histiocytosis Amyotrophic lateral sclerosis – Basic Information Turner’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Frexalimab GSKVX000000030810 Raxtozinameran Flutamide Cln-081 Thiopental Sodium Ponatinib Methotrexate Disodium Daunorubicin Hydrochloride Eribulin Depemokimab DCC-3084 Plerixafor Calcifediol Afatinib Taldefgrobep Alfa At-1501 [18F]-Altanserin Fludeoxyglucose (18F) Gadobenate Dimeglumine More therapies…

    Learn about Your Condition

    Pyrexia Combined immunodeficiency Abdominal infection Venous thrombosis limb Idiopathic pulmonary fibrosis Atrophic vulvovaginitis Anal incontinence Progressive supranuclear palsy Eye pain Acute promyelocytic leukaemia Acute lymphocytic leukaemia Transitional cell carcinoma Endometriosis Cervix carcinoma stage II Urinary tract infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Koranyi National Institute For Pulmonology

Koranyi National Institute For Pulmonology

Koranyi Frigyes Ut 1, Budapest, 1121, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Mrna-4157
    • Carboplatin
    • Cisplatin
    Belgium Bulgaria Finland France Germany Greece +8

  • Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

    Recruiting

    2 1
    Investigated Diseases:
    • Acute respiratory distress syndrome
    Investigated Drugs:
    • Human Plasma Gelsolin, Recombinant
    Belgium Bulgaria Czechia France Germany Hungary +4

  • Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    • Bi 1015550
    Austria Belgium Croatia Czechia Denmark Estonia +14

  • Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Formoterol Fumarate Dihydrate
    • Glycopyrronium Bromide
    • Salbutamol
    Austria Bulgaria Czechia Denmark Finland France +10

  • Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium Germany Hungary Italy Poland +1

  • Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Cemiplimab
    Bulgaria Hungary Poland Romania

  • A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Cetuximab
    • Mk-1084
    Germany Greece Hungary Italy Poland Spain

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Budesonide
    • Divarasib
    • Carboplatin
    Belgium Denmark France Germany Greece Hungary +6

  • Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • H2-Receptor Antagonists
    • Buclizine Hydrochloride
    • Carboplatin
    Austria Czechia France Germany Hungary Ireland +4

  • Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Adagrasib
    • Pembrolizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +13
Previous Page
1 2 3 4 5 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!